SunTrust Downgrades NewLink Genetics (NLNK) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to SunTrust Downgrades NewLink Genetics (NLNK) to Neutral

NewLink Genetics (NLNK) Phase 3 Study of Algenpantucel-L Did Not Achieve Primary Endpoint

May 9, 2016 4:03 PM EDT

NewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.

The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Overall survival from time of randomization was 29.3 months for both groups combined. There was no statistically significant difference between the two groups. The... More